Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

(2015) A. C. Rawstron et al.   BLOOD

Medical devices: US medical device regulation

(2015) Jonathan P. Jarow et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Utility of Nine-Color, 11-Parameter Flow Cytometry for Detection of Plasma Cell Neoplasms

(2014) Amir Behdad et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

(2014) Ola Landgren et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds

(2014) Tomas Kalina et al.   CYTOMETRY PART A

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy

(2014) Stéphanie Mathis et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

ICSH/ICCS practice guidelines special issue

(2013) Marie-Christine Béné et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part I - rationale and aims

(2013) Bruce H. Davis et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations

(2013) David Barnett et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part III - analytical issues

(2013) Shabnam Tanqri et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues

(2013) Bruce H. Davis et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria

(2013) Brent Wood et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease in Multiple Myeloma

(2013) Nikhil C. Munshi et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma

(2013) N Robillard et al.   Blood Cancer Journal

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Accelerated Approval of Oncology Products: The Food and Drug Administration Experience

(2011) John R. Johnson et al.   JNCI-Journal of the National Cancer Institute

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD